Constipation is an unsatisfactory defecation distinguished by difficult stool passage, infrequent stools or both.
Difficult stool passage may include straining, feeling of difficulty in passing stool, incomplete evacuation, lumpy/hard stools, prolonged time to defecate, need for manual maneuver to pass stool, abdominal discomfort and feeling of anorectal blockade.
Chronic constipation is considered when symptoms of constipation have existed ≥3 months.
Symptoms of chronic constipation may be due to dysfunction of intestinal motility, visceral sensitivity, anorectal musculature or the enteric nervous system.
Use of plecanatide for treating elderly patients with chronic idiopathic constipation (CIC) or irritable bowel syndrome with constipation (IBS-C) is well tolerated and improves stool frequency and form, proving to be just as safe and effective as it is in younger populations, as shown in a recent study.
Transabdominal interferential electrical stimulation induces bowel symptom improvements in chronically constipated women, and the effects may be sustained 3 months after therapy, according to the results of a trial.
A 4-week treatment course of Bifidobacterium lactis NCC2818 in patients with chronic mild constipation does not appear to confer benefits for whole gut transit time and for other constipation-related outcomes, such as stool frequency and stool consistency, a study reports.
New drug applications approved by US FDA as of 01- 15 December 2018
which includes New Molecular Entities (NMEs) and new biologics. It does
not include Tentative Approvals. Supplemental approvals may have
occurred since the original approval date.
The novel local-acting ileal bile acid transporter inhibitor elobixibat helps relieve chronic constipation in the short term, with well tolerated safety profile in the long term — supporting the novel approach of increasing intracolonic bile acid concentration for treating chronic constipation, two phase III studies show.
Depression appears to be a stronger predictor of absenteeism than symptom severity in patients with chronic constipation, suggests a study, adding that depression may partly contribute to the indirect costs of chronic constipation.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Gastroenterology - Malaysia digital copy today!
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.